Anti-LE™1 monoclonal antibody

Pre-made anti-LE™1 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to LE™1/LE™1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP1082-Ab-1/ GM-Tg-hg-IP1082-Ab-2Anti-Human LE™1 monoclonal antibodyHuman
GM-Tg-rg-IP1082-Ab-1/ GM-Tg-rg-IP1082-Ab-2Anti-Rat LE™1 monoclonal antibodyRat
GM-Tg-mg-IP1082-Ab-1/ GM-Tg-mg-IP1082-Ab-2Anti-Mouse LE™1 monoclonal antibodyMouse
GM-Tg-cynog-IP1082-Ab-1/ GM-Tg-cynog-IP1082-Ab-2Anti-Cynomolgus/ Rhesus macaque LE™1 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP1082-Ab-1/ GM-Tg-felg-IP1082-Ab-2Anti-Feline LE™1 monoclonal antibodyFeline
GM-Tg-cang-IP1082-Ab-1/ GM-Tg-cang-IP1082-Ab-2Anti-Canine LE™1 monoclonal antibodyCanine
GM-Tg-bovg-IP1082-Ab-1/ GM-Tg-bovg-IP1082-Ab-2Anti-Bovine LE™1 monoclonal antibodyBovine
GM-Tg-equg-IP1082-Ab-1/ GM-Tg-equg-IP1082-Ab-2Anti-Equine LE™1 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP1082-Ab-1/ GM-Tg-hg-IP1082-Ab-2; GM-Tg-rg-IP1082-Ab-1/ GM-Tg-rg-IP1082-Ab-2;
GM-Tg-mg-IP1082-Ab-1/ GM-Tg-mg-IP1082-Ab-2; GM-Tg-cynog-IP1082-Ab-1/ GM-Tg-cynog-IP1082-Ab-2;
GM-Tg-felg-IP1082-Ab-1/ GM-Tg-felg-IP1082-Ab-2; GM-Tg-cang-IP1082-Ab-1/ GM-Tg-cang-IP1082-Ab-2;
GM-Tg-bovg-IP1082-Ab-1/ GM-Tg-bovg-IP1082-Ab-2; GM-Tg-equg-IP1082-Ab-1/ GM-Tg-equg-IP1082-Ab-2
Products NameAnti-LE™1 monoclonal antibody
Formatmab
Target NameLE™1
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-LE™1 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP1082-Ag-1Recombinant multi-species LE™1/ SLC55A1 protein


    Target information

    Target IDGM-IP1082
    Target NameLE™1
    Gene ID3954,56384,305457,722530,488807,101082904,513324
    Gene Symbol and SynonymsCONDMIM,KHE,LE™1,Mdm38,SLC55A1
    Uniprot AccessionO95202,Q5XIN6,Q0VCA3
    Uniprot Entry NameLE™1_HUMAN,LE™1_RAT,LE™1_BOVIN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000168924
    Target ClassificationN/A

    The target: LE™1, gene name: LE™1, also named as SLC55A1. This gene encodes a protein that is localized to the inner mitochondrial membrane. The protein functions to maintain the mitochondrial tubular shapes and is required for normal mitochondrial morphology and cellular viability. Mutations in this gene cause Wolf-Hirschhorn syndrome, a complex malformation syndrome caused by the deletion of parts of the distal short arm of chromosome 4. Related pseudogenes have been identified on chromosomes 8, 15 and 19. [provided by RefSeq, Oct 2009].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.